Brawn Biotech Limited

Company Profile

Brawn Biotech Limited had its IPO on under the ticker symbol 530207.

The company operates in the Other sector and Other industry. Brawn Biotech Limited has a staff strength of 59 employees.

Stock update

Shares of Brawn Biotech Limited opened at ₹24.83 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹23.5 - ₹24.84, and closed at ₹23.92.

This is a +1.1% increase from the previous day's closing price.

A total volume of 0 shares were traded at the close of the day’s session.

In the last one week, shares of Brawn Biotech Limited have increased by +5.84%.

Brawn Biotech Limited's Key Ratios

Brawn Biotech Limited has a market cap of ₹62.11 million, indicating a price to book ratio of 0.6636 and a price to sales ratio of 0.1627.

In the last 12-months Brawn Biotech Limited’s revenue was ₹369.77 million with a gross profit of ₹74.70 million and an EBITDA of ₹0. The EBITDA ratio measures Brawn Biotech Limited's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Brawn Biotech Limited’s operating margin was -2.89% while its return on assets stood at 0% with a return of equity of 0%.

In Q3, Brawn Biotech Limited’s quarterly earnings growth was a negative -74% while revenue growth was a negative 18.3%.

Brawn Biotech Limited’s PE and PEG Ratio

Forward PE

0

Trailing PE

6.1542

PEG

Its diluted EPS in the last 12-months stands at ₹-3.946 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Brawn Biotech Limited’s profitability.

Brawn Biotech Limited stock is trading at a EV to sales ratio of 0.1502 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.1627.

Brawn Biotech Limited stock pays annual dividends of ₹ per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

₹178.02 million

Total Liabilities

₹86.02 million

Operating Cash Flow

₹0

Capital Expenditure

₹0

Dividend Payout Ratio

0%

Brawn Biotech Limited ended 2024 with ₹178.02 million in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹178.02 million while shareholder equity stood at ₹90.65 million.

Brawn Biotech Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹86.02 million in other current liabilities, 30003000.00 in common stock, ₹0 in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹3.41 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹0.

Brawn Biotech Limited’s total current assets stands at ₹175.47 million while long-term investments were ₹0 and short-term investments were ₹1.22 million. Its net receivables were ₹138.58 million compared to accounts payable of ₹66.91 million and inventory worth ₹4.83 million.

In 2024, Brawn Biotech Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.

Comparatively, Brawn Biotech Limited paid ₹0 in dividends in 2024.

Other key metrics

Current Trading Price

₹23.92

52-Week High

₹24.84

52-Week Low

₹14.36

Analyst Target Price

₹

Brawn Biotech Limited stock is currently trading at ₹23.92 per share. It touched a 52-week high of ₹24.84 and a 52-week low of ₹24.84. Analysts tracking the stock have a 12-month average target price of ₹.

Its 50-day moving average was ₹18.14 and 200-day moving average was ₹18.18 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 5616.1% of the company’s stock are held by insiders while 0% are held by institutions.